STAT 39.1%
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A soars
By Allison DeAngelis - 7/6/2026, 8:52 PM - 113 words
Faulty reasoning signals
- Confirmation Bias - 0%
- Anchoring Bias - 0%
- Availability Heuristic - 0%
- Representativeness Heuristic - 0%
- Hindsight Bias - 0%
- Overconfidence Bias - 0%
- Framing Effect - 42.5% (48 hits)
- Loss Aversion - 0%
- Status Quo Bias - 0%
- Sunk Cost Effect - 0%
- Optimism Bias - 32.7% (37 hits)
- Pessimism Bias - 0%
Article text
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A soars
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies announced Monday.
Through the deal, Vertex will pick up Crinetics’ commercial drug, Palsonify, which was launched last year and which treats a rare endocrine disorder called acromegaly, as well as other drug candidates that have blockbuster potential if approved.
The company is also in the late stages of developing a therapy for congenital adrenal hyperplasia.
The $10 billion price tag for Crinetics amounts to roughly $85 per share of the company’s stock.
Following the news, Crinetics shares rose 101% in after-hours trading.